.svg)
Benign Prostatic Hyperplasia and the PSA Story
BPH biomarkers are measurable signals in blood that come from the prostate and mirror how large and active the gland has become with benign overgrowth. The core marker is prostate‑specific antigen (PSA), a protein made by prostate lining cells that normally stays inside prostate ducts and semen; when the gland enlarges or its lining turns over faster, more leaks into the bloodstream. Tests that look at PSA and its related forms—free PSA (unbound PSA), precursor PSA (proPSA, especially [-2]proPSA), and human kallikrein 2 (hK2)—capture different facets of prostate biology (kallikrein‑related peptidases). Together they reflect gland volume, ductal integrity, and secretory activity, giving a biochemical readout of BPH rather than just symptom scores. No single blood marker “proves” BPH, but patterns in these prostate‑derived proteins help separate benign enlargement from other prostate conditions, indicate when more evaluation may be useful, and provide a simple way to track the gland’s behavior over time. Hormone signals that drive growth (androgens such as testosterone and dihydrotestosterone) are related context but are not prostate‑specific biomarkers.
Why a PSA Pattern Matters in Prostate Enlargement
Blood testing for BPH focuses on prostate-derived markers—especially Total PSA and the fraction that circulates unbound (Free PSA or percent‑free). Because PSA production rises with gland size and epithelial turnover, these markers translate prostate biology into a signal about urinary tract function, bladder workload, and even kidney stress when outflow is obstructed.Total PSA tends to increase with age and prostate volume; age-adjusted reference ranges are used, but for most men the healthiest pattern is a lower Total PSA for age. Percent‑free PSA helps interpret why PSA is elevated: higher percentages are more consistent with benign overgrowth, while lower percentages can indicate a greater likelihood of cancer. In BPH, Total PSA that sits toward the mid-to-higher end of the age range often reflects a larger prostate and higher risk of weak stream, urgency, or nocturia; a higher percent‑free PSA in that setting supports a benign process.When values are low—low Total PSA, often with a higher percent‑free—this usually means a smaller gland, less epithelial activity and inflammation, and minimal obstruction. Younger men typically show very low levels; in older men, low PSA suggests low BPH burden. Urinary symptoms, if present despite low values, may be driven more by bladder function than by prostate blockage. Certain medicines that shrink the prostate can lower PSA and require context for interpretation.Big picture: PSA biology sits at the crossroads of hormones, growth signaling, and inflammation. Tracking Total and Free PSA connects prostate size to bladder health and kidney protection, and, alongside exam and imaging, helps distinguish benign enlargement from malignancy—clarifying long‑term risks from urinary retention to renal impairment.
What PSA Can and Can't Say About BPH
Benign prostatic hyperplasia (BPH) is a common, non-cancerous enlargement of the prostate gland that can affect urinary, reproductive, and overall metabolic health, especially as men age. At Superpower, we assess BPH risk and status by measuring two key blood biomarkers: PSA Total and Free PSA. These markers help us understand how the prostate is functioning and whether its growth is stable or showing signs of abnormality, which can impact energy, urinary flow, and even aspects of cardiovascular and immune system health.PSA Total (prostate-specific antigen) is a protein produced by both normal and enlarged prostate tissue. Free PSA refers to the fraction of PSA circulating in the blood that is not bound to other proteins. In BPH, both PSA Total and Free PSA can be elevated, but the ratio between them helps distinguish benign enlargement from more concerning conditions like prostate cancer. A higher proportion of Free PSA relative to Total PSA is more typical of BPH, while a lower ratio may warrant further investigation.Stable and healthy prostate function is reflected by PSA levels that remain within an expected range for age and by a Free-to-Total PSA ratio that supports a benign process. These markers, when interpreted together, provide insight into the balance and integrity of prostate tissue, helping to monitor for changes that could affect urinary and systemic health.It’s important to note that PSA levels can be influenced by age, recent ejaculation, prostate manipulation, infections, and certain medications. Laboratory methods and reference ranges may also vary, so results are best interpreted in context with clinical history and other findings.
FAQs
BPH blood testing looks at proteins made by prostate cells to gauge prostate activity. The key marker is PSA, measured as Total PSA and Free PSA (percent-free PSA helps refine what’s causing the rise). Superpower tests your blood for PSA Total and Free PSA. Elevated PSA can reflect benign enlargement (BPH), inflammation or infection (prostatitis), recent manipulation, or less commonly prostate cancer. This test does not diagnose BPH or cancer by itself; it adds objective biology to your symptom story and exam.
It gives a baseline and trend for prostate biology. Total PSA reflects how active and enlarged the prostate is. The Free PSA percentage improves specificity: higher percent-free PSA leans toward benign causes like BPH; lower percent-free PSA raises concern for other pathology. Together with symptoms and exam, these results help separate common enlargement from inflammation or higher-risk conditions and guide whether further evaluation is needed.
Yes. With Superpower, our team member can organize a blood draw in your home. We collect a standard venous sample, process it securely, and report your Total PSA and Free PSA with clear context and interpretation notes. No clinic visit is required.
For most, an annual PSA provides meaningful trend data. If a result is unexpectedly high, a short-interval repeat after transient factors resolve can confirm whether it’s a true change. Testing frequency also varies with age, prostate size, prior PSA levels, family history, and any recent infections or procedures. Trends over time are more informative than any single value.
Age and prostate size naturally raise PSA. Prostatitis, urinary tract infection, urinary retention, recent ejaculation, vigorous cycling, catheterization, cystoscopy, massage, or biopsy can temporarily increase levels. 5‑alpha‑reductase inhibitors (finasteride, dutasteride) lower PSA roughly by half after sustained use; testosterone therapy can raise it. Recent instrumentation or infection can shift results for weeks. Minor day‑to‑day and lab variability also occur.
Fasting is not required. Avoid ejaculation and vigorous cycling for 24–48 hours. Ideally draw before prostate manipulation; wait several weeks after infection, catheterization, or biopsy. If you take finasteride or dutasteride, PSA values are expected to run lower and should be interpreted with that adjustment. Stay well hydrated and schedule the test when you are free of urinary symptoms from an acute infection.
References
- Polascik, T. J., Oesterling, J. E., & Partin, A. W. (1999). Prostate specific antigen: a decade of discovery--what we have learned and where we are going. The Journal of Urology, 162(2), 293-306. https://doi.org/10.1016/s0022-5347(05)68543-6
- Catalona, W. J., Smith, D. S., Wolfert, R. L., Wang, T. J., Rittenhouse, H. G., Ratliff, T. L., & Nadler, R. B. (1995). Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA, 274(15), 1214-1220. https://doi.org/10.1001/jama.1995.03530150038031
- Jung, K., Brux, B., Lein, M., Knabich, A., Sinha, P., Rudolph, B., Schnorr, D., & Loening, S. A. (1999). Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA. Urology, 53(6), 1160-1168. https://doi.org/10.1016/s0090-4295(99)00080-1
- Jansen, F. H., van Schaik, R. H., Kurstjens, J., Horninger, W., Klocker, H., Bektic, J., Wildhagen, M. F., Roobol, M. J., Bangma, C. H., & Bartsch, G. (2010). Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. European Urology, 57(6), 921-927. https://doi.org/10.1016/j.eururo.2010.02.003
- Sokoll, L. J., Sanda, M. G., Feng, Z., Kagan, J., Mizrahi, I. A., Broyles, D. L., Partin, A. W., Srivastava, S., Thompson, I. M., Wei, J. T., Zhang, Z., & Chan, D. W. (2010). A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiology, Biomarkers & Prevention, 19(5), 1193-1200. https://doi.org/10.1158/1055-9965.epi-10-0007
- Verhamme, K. M., Dieleman, J. P., Bleumink, G. S., van der Lei, J., Sturkenboom, M. C., & Triumph Pan European Expert Panel. (2002). Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project. European Urology, 42(4), 323-328. https://doi.org/10.1016/s0302-2838(02)00354-8
.avif)
.svg)
.svg)
